eCite Digital Repository
Belimumab Therapy for Systemic Lupus Erythematosus and Potential Treatment of Rheumatoid Arthritis
Citation
Ding, C and Li, R and Xu, J and Cicuttini, F and Jones, G, Belimumab Therapy for Systemic Lupus Erythematosus and Potential Treatment of Rheumatoid Arthritis, Drug Development Research, 72, (7) pp. 623-633. ISSN 0272-4391 (2011) [Refereed Article]
![]() | PDF Restricted - Request a copy 188Kb |
Copyright Statement
The definitive published version is available online at: http://www3.interscience.wiley.com/
Abstract
B-lymphocyte stimulator (BLyS) maintains the survival of B cells, and is elevated in serum
or locally in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Belimumab
(LymphoStat-B) is a fully human IgG1l monoclonal antibody that binds to soluble human BLyS and
inhibits its biological activity. It has been developed for therapy for SLE and the potential treatment of other
autoimmune diseases. Belimumab was well tolerated in the treatment of SLE for more than 5 years and of
RA for more than 24 weeks. In the pooled analyses of two Phase III trials including 1,684 seropositive SLE
patients, a statistically significant improvement was observed for the SLE responder index at week 52 for
belimumab 1 mg/kg and 10 mg/kg as compared with placebo (46% vs 39%, P50.006; 51% vs 39%,
Po0.0001, respectively). It modestly reduced the signs and symptoms of RA, most notably in subgroups
such as patients with high disease activity, positive rheumatoid factor, and no prior anti-tumor necrosis
factor (TNF) treatment. Belimumab has been approved by the US Food and Drug Administration for the
treatment of adult patients with active and seropositive SLE who are receiving standard therapy, but its
place in the treatment of RA and other autoimmune diseases remains uncertain.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | B-lymphocyte stimulator (BLyS); belimumab; systemic lupus erythematosus (SLE); rheumatoid arthritis (RA) |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Clinical sciences |
Research Field: | Rheumatology and arthritis |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Ding, C (Professor Chang-Hai Ding) |
UTAS Author: | Jones, G (Professor Graeme Jones) |
ID Code: | 75530 |
Year Published: | 2011 |
Deposited By: | Menzies Institute for Medical Research |
Deposited On: | 2012-02-02 |
Last Modified: | 2017-11-02 |
Downloads: | 0 |
Repository Staff Only: item control page